Original article

Neuron-specific enolase kinetics: an additional tool for neurological prognostication after cardiac arrest

Pedro Martínez-Losada, a,∗ Esteban López de Sá, a Eduardo Armada, a Sandra Rosillo, a María Carmen Monedero, a Juan Ramón Rey, a Juan Caro-Codón, a Antonio Buño Soto, b and José Luis López Sendón a

a Servicio de Cardiología, Hospital Universitario La Paz, IdiPaz, CIBERCV, Madrid, Spain
b Servicio de Andalucía Clínica, Hospital Universitario La Paz, IdiPaz, Madrid, Spain

A B S T R A C T

Introduction and objectives: To analyze neuron-specific enolase (NSE) kinetics as a prognostic biomarker of neurological outcome in cardiac arrest survivors treated with targeted temperature management.

Methods: We performed a retrospective analysis of patients admitted from in- or out-of-hospital cardiac arrest admitted from September 2006 to May 2018 in a single tertiary care center and cooled to 32 °C to 34 °C for 24 hours. Blood samples for measurement of NSE values were drawn at hospital admission and at 24, 48, and 72 hours after return of spontaneous circulation (ROSC). Neurological outcome was evaluated by means of the Cerebral Performance Category (CPC) score at 3 months and was characterized as good (CPC 1-2) or poor (CPC 3-5).

Results: Of 451 patients, 320 fulfilled the inclusion criteria and were analyzed (80.3% male, mean age 61 ± 14.1 years). Among these, 174 patients (54.4%) survived with good neurological status. Poor outcome patients had higher median NSE values at hospital admission and at 24, 48 and 72 hours after ROSC. At 48 and 72 hours after ROSC, NSE predicted poor neurological outcome with areas under the receiver-operating characteristic curves of 0.85 (95%CI, 0.81-0.90) and 0.88 (95%CI, 0.83-0.93), respectively. In addition, delta NSE values between 72 hours after ROSC and hospital admission predicted poor neurological outcome with an area under the receiver-operating characteristic curve of 0.90 (95%CI, 0.85-0.95) and was an independent predictor of unfavorable outcome on multivariate analysis (P < .001).

Conclusions: In cardiac arrest survivors treated with targeted temperature management, delta NSE values between 72 hours after ROSC and hospital admission strongly predicted poor neurological outcome.

© 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Cinética de la enolasa neuroespecífica: una herramienta adicional para el pronóstico neurológico después de una parada cardíaca

R E S U M E N

Introducción y objetivos: Analizar la cinética de la enolasa neuroespecífica (EN) como biomarcador de pronóstico neurológico de los pacientes que sobreviven a una parada cardíaca tratados con control de temperatura.

Métodos: Análisis retrospectivo de pacientes ingresados tras sufrir una parada cardíaca dentro o fuera del hospital del 1 de septiembre de 2006 y mayo de 2018 en un centro terciario y enfriados a 32-34 ºC durante 24 h. Las muestras de EN se tomaron al ingreso hospitalario y a las 24, 48 y 72 h del retorno a circulación espontánea (RCE). El estado neurológico se evaluó a los 3 meses mediante la escala Cerebral Performance Category (CPC) y se categorizó como favorable (CPC 1-2) o desfavorable (CPC 3-5).

Resultados: De los 451 pacientes, 320 cumplían los criterios de inclusión (el 80,3% varones; media de edad, 61 ± 14,1 años). De estos, 174 (54,4%) sobrevivieron con una evolución neurológica favorable. Los pacientes con estado neurológico desfavorable tenían valores de EN más altos al ingreso hospitalario y a las 24, 48 y 72 h del RCE. A las 48 y las 72 h, los valores de EN predijeron un estado neurológico desfavorable, con áreas bajo la curva de 0,85 (IC95%, 0,81-0,90) y 0,88 (IC95%, 0,83-0,93). Además, el área bajo la curva de los valores delta de EN entre las 72 h y el ingreso hospitalario fue de 0,90 (IC95%, 0,85-0,95), y en el análisis multivariante resultó predictor independiente (p < .001).

* Corresponding author: Servicio de Cardiología. Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
E-mail address: martinezlosada@gmail.com (P. Martínez-Losada).

https://doi.org/10.1016/j.rec.2019.01.008
1885-5857/© 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
INTRODUCCIÓN

Sudden cardiac arrest (CA) es uno de los más comunes causas de muerte en el mundo desarrollado, afectando a cerca de 550 000 personas anualmente en los Estados Unidos. Aunque una proporción de CA muertes ocurren antes de, o durante la reanimación, un porcentaje significativo de las muertes ocurre después de una dilación en pacientes con historia de CA exitosamente resucitados y eventualmente admitidos en un servicio de cuidados intensivos. En estos pacientes, la mayoría de la mortalidad se debe a la inestabilidad hemodinámica, mientras que el daño cerebral resultante de la desencadenación de los eventos no está documentado para la mayoría de los días siguientes. En general, la retirada del soporte vital frecuentemente se realiza previo a que se incurra en la normothermia en pacientes con comas post-CA. La pérdida de estos pacientes se debe al daño cerebral que es una causa importante de la alta mortalidad en esta población. Algunos estudios han demostrado que la extracción de enzimas neuronales como la enolasa neuronal específica (NSE) durante los primeros días después del CA, uno de los factores de riesgo predictivos, es un predictor de la alta mortalidad cerebral y la presencia de signos clínicos de daño cerebral. Por lo tanto, el uso de la NSE y la enolasa como marcadores de daño cerebral en pacientes con CA ha adquirido un interés creciente.

En el año 2009, hemos incluido la evaluación de NSE en los pacientes con CA en nuestro centro, obteniendo resultados prometedores. Los objetivos del presente estudio son: 1) Analizar los resultados clínicos de los pacientes con CA en función de las concentraciones de NSE en suero y 2) Describir el uso de la NSE como un marcador de pronóstico de la supervivencia cerebral en los pacientes con CA.

MÉTODOS

La técnica de CA escalar prospectiva en pacientes con CA, con el consentimiento informado y el consentimiento verbal si se preveía la ausencia de semiconciencia. El ritmo de la relación de CA se practicó en el CIC de la Academia de la Universidad de la Salud. La evolución del paciente fue monitorizada mediante la monitorización electrofisiológica (EFM). Los pacientes con CA fueron tratados con una terapia intensiva con controles de temperatura (TTM) que se realizaron a intervalos de 12 horas. La concentración de NSE se midió en suero y en la sangre arterial en los primeros 24 horas después de la CA. La terapia con NSE se realizó en función de las concentraciones de NSE en el suero y la sangre arterial.

Conclusiones: En pacientes que sobrevivieron a una parada cardíaca tratados con control de la temperatura, se ha demostrado que los valores de NSE muestran una alta sensibilidad y especificidad para la detección del daño cerebral. Se recomienda la realización de estudios adicionales para confirmar estos resultados en un número mayor de pacientes.

© 2019 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

ABBREVIATIONS

CA: cardiac arrest
CPC: Cerebral Performance Category
NSE: neuron-specific enolase
ROC-AUC: area under the receiver-operating characteristic curve
ROSC: return of spontaneous circulation
TTM: targeted temperature management

Desde 2009, hemos incluido la evaluación de las concentraciones de NSE en pacientes con CA en nuestro centro, obteniendo resultados prometedores. Los objetivos del presente estudio son: 1) Analizar los resultados clínicos de los pacientes con CA en función de las concentraciones de NSE en suero y 2) Describir el uso de la NSE como un marcador de pronóstico de la supervivencia cerebral en los pacientes con CA. Desde 2009, hemos incluido la evaluación de las concentraciones de NSE en pacientes con CA en nuestro centro, obteniendo resultados prometedores. Los objetivos del presente estudio son: 1) Analizar los resultados clínicos de los pacientes con CA en función de las concentraciones de NSE en suero y 2) Describir el uso de la NSE como un marcador de pronóstico de la supervivencia cerebral en los pacientes con CA.
and neuroimaging findings, a multidisciplinary team established WLST, always in agreement with the patient’s representatives.

The primary outcome of the study was the best neurological functional status achieved 3 months after CA determined according to the Pittsburgh Cerebral Performance Category (CPC) score and characterized for the purpose of the present analysis as good (CPC 1-2) or poor (CPC 3-5). A CPC score of 3 to 5 is equivalent to severe disability, coma, or death. Neurological status information was assessed retrospectively based on routine postcardiac arrest medical follow-up or by telephone interviews with patients and/or close family members.

**Statistics**

Continuous variables are presented as means ± standard deviation and were compared using the Student t test for normally distributed values; otherwise, variables are described as medians and interquartile range [IQR] and differences were analyzed with the Mann-Whitney U test. The Fisher exact test was used to compare proportions. The discriminatory power of NSE to predict an unfavorable neurological outcome was determined by analysis of receiver-operating characteristics (ROC) curves. Different NSE thresholds for poor neurological outcome were provided as a compromise between sensitivity and specificity by maximizing the Youden index (defined as sensitivity + specificity -1) and by providing 95% to 100% specificity.

Multivariate analysis was performed using stepwise logistic regression analysis. All variables that were statistically significant on univariate analysis were selected as candidate variables for the predictive model. To avoid collinearity, the parameter with the highest area under the curve among NSE determinations (delta NSE value between 72 hours after ROSC and hospital admission) was selected as a candidate variable. The results are expressed as odds ratios (OR) and their 95% confidence intervals (95%CI). The Hosmer-Lemeshow test was used to determine the goodness-of-fit of the model. The additional predictive power contributed by the delta NSE value was evaluated using the net reclassification index (NRI) and the integrated discrimination improvement (IDI).

This model was compared with others that included different delta or absolute NSE values. In all models, missing data were excluded from the analysis using listwise deletion. The significance level was set at P < .05. All statistical analyses were performed using Stata v14.2 (StataCorp, College Station, Texas, United States).

**RESULTS**

**Clinical characteristics**

During the study period, a total of 451 survivors of in- or out-of-hospital CA were consecutively admitted to our ACCU and treated with TTM. Of these, 89 patients were excluded due to the absence of any NSE determinations during admission. Excluded patients were mostly part of the initial 2006 to 2009 period when NSE analysis was not part of our postresuscitation protocol. Additionally, 40 patients died within 72 hours and 2 patients were lost to follow-up. Ultimately, 320 patients were included in the final statistics analysis (Figure 1).

The mean age of the cohort was 61 ± 14.1 years and 80.2% were male. In all, 281 patients (87.8%) had an out-of-hospital CA and 220 (68.7%) had an initial shockable rhythm (pulsless ventricular tachycardia or ventricular fibrillation). According to the CPC scale, 174 patients (54.4%) were assigned to the good neurological outcome group (CPC 1-2) vs 146 (45.6%) who were assigned to the poor neurological group (CPC 3-5) at 3-months’ follow-up. In the poor neurological outcome group, 9 patients were assigned to CPC 3, 1 patient to CPC 4 and 136 to CPC 5. The good neurological outcome group was younger, with shorter ROSC times (including no flow and low flow) and had a higher percentage of initial shockable rhythms and less altered pH values, serum lactate, and glucose levels at hospital admission. The clinical characteristics of all included patients in the study and according to the CPC scale are shown in Table 1.

NSE determinations were available in 202 patients at hospital admission, 289 on day 1, 287 on day 2, and 223 on day 3. Additionally, available delta NSE values were 195 between day 1

---

**Figure 1.** Flow diagram of patients included in the study. CA, cardiac arrest; CPC, Cerebral Performance Category; TH, therapeutic hypothermia.
Table 1  
Clinical and laboratory characteristics of the overall cohort and stratified by neurological outcome

<table>
<thead>
<tr>
<th></th>
<th>All patients (n = 320)</th>
<th>CPC 1-2 (n = 174)</th>
<th>CPC 3-5 (n = 146)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>61 ± 14.7</td>
<td>59.5 ± 14.7</td>
<td>64.1 ± 14.4</td>
<td>.003</td>
</tr>
<tr>
<td>Male sex</td>
<td>257 (80.3)</td>
<td>145 (83.3)</td>
<td>112 (76.7)</td>
<td>.16</td>
</tr>
<tr>
<td>Hypertension</td>
<td>164 (51.2)</td>
<td>84 (48.3)</td>
<td>80 (54.8)</td>
<td>.19</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>77 (24.1)</td>
<td>30 (17.2)</td>
<td>47 (32.2)</td>
<td>.001</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>128 (40)</td>
<td>74 (42.5)</td>
<td>54 (37)</td>
<td>.41</td>
</tr>
<tr>
<td>Current smoker</td>
<td>151 (47.2)</td>
<td>88 (50.6)</td>
<td>63 (43.1)</td>
<td>.24</td>
</tr>
<tr>
<td>Shockable initial rhythm</td>
<td>220 (68.7)</td>
<td>150 (86.2)</td>
<td>70 (47.9)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Out-of-hospital CA</td>
<td>281 (87.8)</td>
<td>150 (86.2)</td>
<td>131 (89.7)</td>
<td>.29</td>
</tr>
<tr>
<td>Witnessed arrest</td>
<td>301 (94.1)</td>
<td>170 (97.7)</td>
<td>131 (89.7)</td>
<td>.003</td>
</tr>
<tr>
<td>Initial pH</td>
<td>7.1 ± 0.1</td>
<td>7.21 ± 0.15</td>
<td>7.13 ± 0.17</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Serum lactate at admission, mmol/L</td>
<td>6.3 ± 4.2</td>
<td>5.3 ± 3.7</td>
<td>7.6 ± 4.4</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Initial glucose level, mg/dL</td>
<td>250.4 ± 99.8</td>
<td>227.9 ± 95.5</td>
<td>277.4 ± 98.5</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

CA, cardiac arrest; CPC, Cerebral Performance Category; ROSC, return of spontaneous circulation.

Data are expressed as no. (%), mean ± standard deviation or median [interquartile range].

and hospital admission, 192 between day 2-admission and 152 between day 3-admission. Patients without a delta NSE value between day 3 and hospital admission had similar baseline characteristics except for a higher percentage of initial nonshockable rhythms (38.1% vs 23.6%; P = .006) and lower pH values at hospital admission (7.15 vs 7.19; P = .028). Furthermore, their NSE values were significantly higher both at 24 hours (77.2 vs 50.8 ng/mL; P < .001) and at 48 hours after ROSC (98.2 vs 63.9 ng/mL; P < .001), and they had a higher percentage of CPC 3-5 score at 3 months (53% vs 37.5%; P = .007). In contrast, patients with no NSE determinations during ACCU admission had higher percentages of in-hospital CA (22.4% vs 12.9%; P = .015) with a tendency to having more unwitnessed CA (12.3% vs 6.6%; P = .052) and initial nonshockable rhythms (38.2% vs 31.7%; P = .154) compared with those patients with at least 1 NSE determination. Indeed, these patients also had a worst neurological outcome at 3 months’ follow-up (CPC 3-5 65.8% vs 51.3%; P = .033).

Neuron-specific enolase values and prediction of poor neurological outcome

Median NSE values were significantly lower at admission in patients with a CPC score 1-2 in comparison with CPC 3-5: 35.6 (IQR, 23.5 to 54.6) vs 47.6 ng/mL (IQR, 29.5 to 64.1; P = .032), 24 hours: 34.0 (IQR, 25.6 to 48.6) vs 59.1 ng/mL (IQR, 35.5 to 94.0; P < .001), 48 hours: 27.9 (IQR, 20 to 38.5) vs 92.0 ng/mL (IQR, 47.9 to 190.7; P < .001), and 72 hours after ROSC: 20.2 (IQR, 14.8 to 30.2) vs 125.8 ng/mL (IQR, 45.9 to 235.3; P < .001) (Figure 2).

The areas under the receiver-operating characteristic curve (ROC-AUC) for NSE at 24, 48 and 72 hours after ROSC for neurological outcome prediction were 0.73 (95%CI, 0.67-0.79), 0.85 (95%CI, 0.81-0.90) and 0.88 (95%CI, 0.83-0.93), respectively (P < .001). Based on the Youden index (sensitivity + specificity - 1), optimal cutoff values for NSE to predict poor neurological outcome were 65.7 ng/mL on day 1 (specificity 90.7% [95%CI, 85.2-94.3],...
sensitivity 45.3% [95%CI, 37.5-53.9]), 57.7 ng/mL on day 2 (specificity 94.2% [95%CI, 89.3-96.9], sensitivity 69.7% [95%CI, 61.4-79.6]) and 45.5 ng/mL on day 3 (specificity 91.7% [95%CI, 85.8-95.3], sensitivity 77.8% [95%CI, 68.2-85.1]). Cutoff values resulting from 95%to 100% specificity in predicting poor neurological outcome are shown in Table 2.

Different delta NSE values were also evaluated to analyze their discriminative ability to predict poor neurological outcome (Figure 3). Of these, delta NSE between day 2 and hospital admission and day 3–admission showed the highest ROC-AUC with 0.82 [95%CI, 0.75-0.88] and 0.90 [95%CI, 0.85-0.95] respectively (P < .001). Optimal cutoff values based on the Youden index were +8.2 ng/mL between day 2 and hospital admission (specificity 90.7% [95%CI, 83.6-94.8], sensitivity 67.1% [95%CI, 56.5-76.1]) and -1.4 ng/mL between day 3 and hospital admission (specificity 85.3% [95%CI, 76.8-91], sensitivity 86% [95%CI, 74.7-92.7]). Cutoff values with 100% specificity for poor neurological outcome were +90.6 ng/mL (sensitivity 37.6%, FPR 0%) between day 2 and hospital admission and +54.9 ng/mL (sensitivity 57.9%, FPR 0%) between day 3 and hospital admission (Table 2).

The selected predictive model using stepwise logistic regression analysis is shown in Table 3. Variables independently associated with a poor neurological outcome at 3 months’ follow-up were known diabetes mellitus (OR, 5.16; 95%CI, 1.35-19.75), initial CA rhythm (shockable rhythm; OR, 0.19; 95%CI, 0.05-0.72) and delta NSE value between 72 hours after ROSC and hospital admission (every 10 ng/mL; OR, 1.97; 95%CI, 1.43-2.72). In addition, there was a tendency toward poor long-term outcome with no-flow time but this did not reach statistical significance (every minute; OR, 1.21; 95%CI, 0.99-1.50). We constructed a ROC curve (ROC-AUC of 0.94; 95%CI, 0.89-0.97) and calculated sensitivity (77.5%) and specificity (94.1%) for the prediction model, with an FPR of 5.9%. This model had a good calibration as assessed with the Hosmer-Lemeshow goodness-of-fit test (P = .62). The delta NSE value showed an NRI of 1.40 (P < .001) and IDI of 0.39 (P < .001). When this individual parameter was excluded from the multivariate model, we observed a significant decrease in the ROC-AUC (0.78; 95%CI, 0.71-0.86; P < .001). Furthermore, the selected model performed better than alternative models that included NSE as a dichotomous variable with different thresholds for the prediction of poor outcome with 100% specificity at 72 hours after ROSC, delta between 48 hours after ROSC and hospital admission, and delta between 72 hours after ROSC and admission (Figure 4).

**DISCUSSION**

The present study describes the kinetics of serum NSE in the first few days after CA in patients treated with TTM and analyzes their correlation with neurological outcome. Despite the simplicity
and accessibility of this biomarker as an additional tool for neurological prognostication and the absence of an effect of sedative agents and TTM on its values or its relative low cost, NSE is still underused in routine clinical practice.\textsuperscript{1,3} This situation probably reflects both technical limitations and the inconclusive results of previous studies, explained by their small sample sizes and the lack of standardization in measuring techniques.\textsuperscript{1,3,15} It follows that the NSE threshold for prediction of poor neurological outcome with 0% FPR in TTM-treated patients varies in the literature between 25 ng/mL and 151.5 ng/mL at 48 hours, and between 57.2 ng/mL and 78.9 ng/mL at 72 hours after ROSC.\textsuperscript{5} In our cohort, although serum NSE values after hospital admission were significantly higher in the CPC 3–5 group than in the CPC 1–2 group, there was still wide variability, especially in the poor neurological outcome group showing, at least in part, the challenge of attempting to generalize a cutoff value of this biomarker with high specificity and narrow confidence intervals (Figure 2). In line with findings of other studies,\textsuperscript{6,16} the best strategy for the use of isolated serum NSE values in our study was at 48 and 72 hours after ROSC with a ROC-AUC of 0.85 and 0.88. In contrast, the predictive ability of NSE at admission and 24 hours after ROSC was significantly lower (ROC-AUC of 0.62 and 0.73, respectively).

Figure 2 also shows the ascending temporal trend of NSE values in the CPC 3–5 group compared with the descending trend in the CPC 1–2 group. Most recent postcardiac arrest care guidelines\textsuperscript{4,17} state that the limited information available on NSE kinetics in the first few days after CA remains a knowledge gap, and therefore a barrier to establishing its usefulness as a prognostic biomarker. Since NSE determination has been part of our postcardiac arrest protocol for 9 years and has been quantified daily from admission to 72 hours after ROSC, the strength of our study lies in the description of NSE kinetics in a large cohort of CA survivors treated with TTM and the assessment of their correlation with the best CPC score at 3 months. In addition, all blood samples from the cohort were analyzed at the same laboratory to reduce variation between different analytical methods. Because the estimated half-life of NSE in serum is approximately 24 hours\textsuperscript{18} an increasing trend in serum NSE values could be explained by ongoing hypoxic brain damage and continuous release from dying neuronal cells in patients with poor neurological outcome.\textsuperscript{19}

Figure 3. Receiver-operating characteristic curves for NSE with their areas under the curve for neurological outcome prediction according to the Cerebral Performance Category scale at 3 months. 95%CI, 95% confidence interval; AUC, area under the receiver-operating characteristic curve; NSE, neuron-specific enolase.

Table 3
<table>
<thead>
<tr>
<th>Variables independently associated with an unfavorable outcome at 3 months after CA\textsuperscript{19}</th>
<th>Poor neurological outcome (CPC 3–5)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unadjusted OR (95%CI)</td>
</tr>
<tr>
<td>No-Flow time (every minute)</td>
<td>1.16 (1.09–1.24)</td>
</tr>
<tr>
<td>Shockable initial rhythm</td>
<td>0.14 (0.08–0.25)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>2.36 (1.39–4.03)</td>
</tr>
<tr>
<td>ΔEnolase 72 h-admission (every 10 ng/mL)</td>
<td>1.66 (1.33–2.06)</td>
</tr>
</tbody>
</table>

95%CI, 95% confidence interval; CA, cardiac arrest; CPC, Cerebral Performance Category; OR: odds ratio.
\textsuperscript{19} n = 134
In our cohort, serum NSE changes between 72 hours after ROSC and hospital admission showed the highest ROC-AUC and the cutoff value of +55 ng/mL represented 100% specificity for poor neurological outcome. In addition, delta serum NSE values were also integrated in a multivariable model in which every 10 ng/mL NSE increase between day 3 and hospital admission showed an OR of 1.97 (95%CI, 1.43-2.72) for poor neurological outcome. Although we did not include variables such as somatosensory evoked potentials, clinical integration or electroencephalogram recordings in our predictive model, the ROC-AUC of the model (0.94; 95%CI, 0.89-0.97) was higher than that of other models proposed in the literature using the recommended multimodal approach. For example, a proposed predictive model by Oddo and Rossetti\(^{20}\) based on a prospective cohort of 134 patients that included clinical examination, EEG, isolated NSE values, and somatosensory evoked potentials showed a ROC-AUC of 0.88 (95%CI, 0.82-0.93) for poor neurological outcome (CPC 3-5) at 3 months of follow-up. This similar prognostic accuracy compared with the isolated NSE values at 72 hours after ROSC and delta NSE values between 72 hours after ROSC and hospital admission in our study strengthens the position of NSE as a prognostic biomarker of neurological outcome in CA survivors. However, NSE is not specific to neuronal damage and can be produced by noncentral nervous system sources (hemolysis, neuroendocrine tumors, myenteric plexus, muscle, and adipose tissue breakdown)\(^{21}\) and its levels could be influenced by age, sex, and body mass index.\(^{21}\) For these reasons, in line with current guidelines and recent studies,\(^{6,19,22}\) we recommend including serum NSE kinetics as part of a multimodal approach based on the integration of different methods to increase its predictive value to identify patients with unfavorable neurological outcome.

The present study has several limitations due to its retrospective nature. First, a substantial number of patients were excluded from the analysis either because of a lack of NSE samples during ACCU admission or because their blood samples showed hemolysis. The number of patients excluded was greater due to the absence of NSE determination at hospital admission or at 72 hours after ROSC, probably given the difficulty of the requirement of this biomarker in the context of an admission for CA and due to a selection bias in view of their worse CA characteristics and neurological outcome. Secondly, serum NSE values were mostly available at the time of neurological prognostication, probably influencing decision-making on WLST. Thirdly, we were not able to include in our predictive model variables such as electroencephalogram recordings, somatosensory evoked potentials, clinical examination, or neuroimaging findings. However, we feel our results represent the current daily practice of a tertiary referral center in postcardiac arrest care that included a substantial cohort of CA survivors in comparison with other studies. A cutoff value of delta NSE +55 ng/mL between 72 hours after ROSC and hospital admission for poor neurological outcome should be evaluated and validated in an external prospective cohort before its implementation in current practice.

CONCLUSIONS

The present study shows that delta NSE value between 72 hours after ROSC and hospital admission has a high predictive value for poor neurological outcome. Our results support the idea that serial NSE measurements rather than isolated values should be included in a multimodal postcardiac arrest neurological prognostication strategy. In our cohort, a delta NSE cutoff value of +55 ng/mL between 72 hours after ROSC and hospital admission showed 100% specificity for poor neurological outcome at 3 months of follow-up after CA.

ACKNOWLEDGEMENTS

The study is funded by the Working Group for Ischemic Heart Disease and Acute Cardiovascular Care of the Spanish Society of Cardiology.

FUNDING

Fellowship for Training and Research in Acute Cardiovascular Care granted by the Working Group for Ischemic Heart Disease and Acute Cardiovascular Care of the Spanish Society Of Cardiology.

CONFLICTS OF INTEREST

None declared.
WHAT IS KNOWN ABOUT THE TOPIC?

- A significant percentage of CA deaths occur in patients admitted into intensive care units. WLST based on a poor neurological prognosis represents the most frequent cause of death in these patients.
- Current resuscitation guidelines recommend basing neurological prognostication after CA on a multimodal approach, including biomarkers such as NSE.
- Current guidelines do not recommend any specific NSE cutoff value for poor neurological prognosis but suggest sampling this enzyme at multiple time-points to detect trends and reduce the risk of false-positive results due to hemolysis. However, the best way to interpret these trend values remains unclear.

WHAT DOES THIS STUDY ADD?

- Since NSE determination has been part of our post-cardiac arrest protocol for 9 years and has been quantified daily from admission to 72 hours after ROSC, the strength of our study lies in the description of NSE kinetics in a large cohort of CA survivors treated with TTM and the assessment of their correlation with the best CPC score at 3 months after CA.

REFERENCES